zolpidem has been researched along with Altered Level of Consciousness in 11 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zolpidem would be a reasonable consideration as an adjunctive treatment in anti-N-methyl-d-aspartate receptor encephalitis after tumor removal and immunotherapy to accelerate recovery and rehabilitation." | 7.80 | Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-D-aspartate receptor encephalitis in a teenager: a case report. ( Appu, M; Noetzel, M, 2014) |
| "Zolpidem has been observed to transiently treat a large variety of neurologic disorders, most often related to movement disorders and disorders of consciousness." | 4.95 | Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. ( Bomalaski, MN; Claflin, ES; Peterson, MD; Townsend, W, 2017) |
| " Zolpidem is a nonbenzodiazepine hypnotic used to treat insomnia that has also been observed to paradoxically improve arousal in those with DOC, such as the vegetative or minimally conscious states." | 4.95 | Improved Arousal and Motor Function Using Zolpidem in a Patient With Space-Occupying Intracranial Lesions: A Case Report. ( Bomalaski, MN; Smith, SR, 2017) |
| "Zolpidem would be a reasonable consideration as an adjunctive treatment in anti-N-methyl-d-aspartate receptor encephalitis after tumor removal and immunotherapy to accelerate recovery and rehabilitation." | 3.80 | Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-D-aspartate receptor encephalitis in a teenager: a case report. ( Appu, M; Noetzel, M, 2014) |
| "Amantadine has been shown to promote the rate of neurologic recovery for patients with traumatic disorders of consciousness when administered between 4 and 16 weeks, as demonstrated by a well-designed randomized control trial." | 3.54 | Pharmacology in Treatment of Patients with Disorders of Consciousness. ( Marino, MH, 2024) |
| "Zolpidem has been reported to cause temporary recovery of consciousness in vegetative and minimally conscious patients, but how often and why this occurs are unknown." | 2.79 | Zolpidem and restoration of consciousness. ( Brunner, R; Demarest, D; Greenwald, B; Kaelin, D; Kalmar, K; Katz, D; Rajan, R; Rosenbaum, A; Seel, R; Whyte, J; Zafonte, R, 2014) |
| "Patients with post-anoxic encephalopathy or traumatic brain injury did not experience benefits of zolpidem." | 2.55 | Potential benefits of zolpidem in disorders of consciousness. ( Khalili, H; Noormandi, A; Shahrokhi, M, 2017) |
| "Zolpidem has been used with mixed effects in patients presenting with Prolonged Disorders of Consciousness (PDOC)." | 1.51 | An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC). ( Cronin, H; Delargy, M; Galligan, I; Gray, D; McCann, A; O'Connor, R; O'Toole, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Q | 1 |
| Hao, J | 1 |
| Kang, X | 1 |
| Yuan, F | 1 |
| Liu, Y | 1 |
| Chen, R | 1 |
| Liu, X | 1 |
| Li, R | 1 |
| Jiang, W | 1 |
| Marino, MH | 1 |
| Noormandi, A | 1 |
| Shahrokhi, M | 1 |
| Khalili, H | 1 |
| Bomalaski, MN | 2 |
| Claflin, ES | 1 |
| Townsend, W | 1 |
| Peterson, MD | 1 |
| Delargy, M | 1 |
| O'Connor, R | 1 |
| McCann, A | 1 |
| Galligan, I | 1 |
| Cronin, H | 1 |
| Gray, D | 1 |
| O'Toole, C | 1 |
| Gosseries, O | 1 |
| Charland-Verville, V | 1 |
| Thonnard, M | 1 |
| Bodart, O | 1 |
| Laureys, S | 1 |
| Demertzi, A | 1 |
| Appu, M | 1 |
| Noetzel, M | 1 |
| Whyte, J | 1 |
| Rajan, R | 1 |
| Rosenbaum, A | 1 |
| Katz, D | 1 |
| Kalmar, K | 1 |
| Seel, R | 1 |
| Greenwald, B | 1 |
| Zafonte, R | 1 |
| Demarest, D | 1 |
| Brunner, R | 1 |
| Kaelin, D | 1 |
| Tucker, C | 1 |
| Sandhu, K | 1 |
| Smith, SR | 1 |
| Clauss, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial of Apomorphine in Severe Brain-injured Patients: a Double-blind Behavioral and Neuroimaging Study[NCT05213169] | Phase 2/Phase 3 | 48 participants (Anticipated) | Interventional | 2021-06-18 | Recruiting | ||
| Treating Severe Brain-injured Patients With Apomorphine: a Behavioral and Neuroimaging Study[NCT03623828] | Phase 2 | 8 participants (Actual) | Interventional | 2018-10-03 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for zolpidem and Altered Level of Consciousness
| Article | Year |
|---|---|
Pharmacology in Treatment of Patients with Disorders of Consciousness.
Topics: Amantadine; Brain Injuries; Consciousness; Consciousness Disorders; Humans; Randomized Controlled Tr | 2024 |
Potential benefits of zolpidem in disorders of consciousness.
Topics: Brain Diseases; Brain Injuries, Traumatic; Consciousness Disorders; GABA-A Receptor Agonists; Humans | 2017 |
Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review.
Topics: Consciousness Disorders; GABA-A Receptor Agonists; Humans; Movement Disorders; Nervous System Diseas | 2017 |
Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.
Topics: Amantadine; Apomorphine; Consciousness Disorders; Humans; Pyridines; Zolpidem | 2014 |
Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.
Topics: Amantadine; Apomorphine; Consciousness Disorders; Humans; Pyridines; Zolpidem | 2014 |
Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.
Topics: Amantadine; Apomorphine; Consciousness Disorders; Humans; Pyridines; Zolpidem | 2014 |
Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.
Topics: Amantadine; Apomorphine; Consciousness Disorders; Humans; Pyridines; Zolpidem | 2014 |
The Effectiveness of Zolpidem for the Treatment of Disorders of Consciousness.
Topics: Consciousness Disorders; GABA-A Receptor Agonists; Humans; Pyridines; Zolpidem | 2016 |
Improved Arousal and Motor Function Using Zolpidem in a Patient With Space-Occupying Intracranial Lesions: A Case Report.
Topics: Arousal; Brain Neoplasms; Consciousness Disorders; Follow-Up Studies; GABA-A Receptor Agonists; Huma | 2017 |
Neurotransmitters in disorders of consciousness and brain damage.
Topics: Antidepressive Agents, Tricyclic; Axons; Baclofen; Consciousness Disorders; Dopamine Agents; Electri | 2011 |
1 trial available for zolpidem and Altered Level of Consciousness
| Article | Year |
|---|---|
Zolpidem and restoration of consciousness.
Topics: Adult; Aged; Consciousness Disorders; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypno | 2014 |
3 other studies available for zolpidem and Altered Level of Consciousness
| Article | Year |
|---|---|
EEG dynamics induced by zolpidem forecast consciousness evolution in prolonged disorders of consciousness.
Topics: Consciousness; Consciousness Disorders; Electroencephalography; Humans; Persistent Vegetative State; | 2023 |
An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC).
Topics: Adult; Awareness; Chronic Disease; Consciousness Disorders; Female; Humans; Hypnotics and Sedatives; | 2019 |
Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-D-aspartate receptor encephalitis in a teenager: a case report.
Topics: Adolescent; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Central Nervous System Agents; Consciou | 2014 |